Application 204824
- Type
- NDA
- Sponsor
- ANTARES PHARMA INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | OTREXUP | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 10MG/0.4ML (10MG/0.4ML) | Yes | Yes |
| 002 | OTREXUP | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 15MG/0.4ML (15MG/0.4ML) | Yes | Yes |
| 003 | OTREXUP | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 20MG/0.4ML (20MG/0.4ML) | Yes | Yes |
| 004 | OTREXUP | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 25MG/0.4ML (25MG/0.4ML) | Yes | Yes |
| 005 | OTREXUP | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 7.5MG/0.4ML (7.5MG/0.4ML) | Yes | No |
| 006 | OTREXUP | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 12.5MG/0.4ML (12.5MG/0.4ML) | Yes | Yes |
| 007 | OTREXUP | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 17.5MG/0.4ML (17.5MG/0.4ML) | Yes | Yes |
| 008 | OTREXUP | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 22.5MG/0.4ML (22.5MG/0.4ML) | Yes | Yes |
| 009 | OTREXUP PFS | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 10MG/0.4ML (10MG/0.4ML) | Yes | No |
| 010 | OTREXUP PFS | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 15MG/0.6ML (15MG/0.6ML) | Yes | No |
| 011 | OTREXUP PFS | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 17.5MG/0.7ML (17.5MG/0.7ML) | Yes | No |
| 012 | OTREXUP PFS | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 20MG/0.8ML (20MG/0.8ML) | Yes | No |
| 013 | OTREXUP PFS | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 22.5MG/0.9ML (22.5MG/0.9ML) | Yes | No |
| 014 | OTREXUP PFS | METHOTREXATE | SOLUTION;SUBCUTANEOUS | 25MG/ML (25MG/ML) | Yes | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N204824-001 | OTREXUP | METHOTREXATE | 10MG/0.4ML (10MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | |
| N204824-002 | OTREXUP | METHOTREXATE | 15MG/0.4ML (15MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | |
| N204824-003 | OTREXUP | METHOTREXATE | 20MG/0.4ML (20MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | |
| N204824-004 | OTREXUP | METHOTREXATE | 25MG/0.4ML (25MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | |
| N204824-005 | OTREXUP | METHOTREXATE | 7.5MG/0.4ML (7.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2014-11-07 | |
| N204824-006 | OTREXUP | METHOTREXATE | 12.5MG/0.4ML (12.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2016-03-24 | |
| N204824-007 | OTREXUP | METHOTREXATE | 17.5MG/0.4ML (17.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2016-03-24 | |
| N204824-008 | OTREXUP | METHOTREXATE | 22.5MG/0.4ML (22.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2016-03-24 | |
| N204824-009 | OTREXUP PFS | METHOTREXATE | 10MG/0.4ML (10MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | |
| N204824-010 | OTREXUP PFS | METHOTREXATE | 15MG/0.6ML (15MG/0.6ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | |
| N204824-011 | OTREXUP PFS | METHOTREXATE | 17.5MG/0.7ML (17.5MG/0.7ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | |
| N204824-012 | OTREXUP PFS | METHOTREXATE | 20MG/0.8ML (20MG/0.8ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | |
| N204824-013 | OTREXUP PFS | METHOTREXATE | 22.5MG/0.9ML (22.5MG/0.9ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | |
| N204824-014 | OTREXUP PFS | METHOTREXATE | 25MG/ML (25MG/ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N204824-001 | 11446441 | 2026-01-24 | Drug product | 2022-10-19 | |
| N204824-001 | 8562564 | 2026-01-24 | Drug product | 2013-11-04 | |
| N204824-001 | 9533102 | 2026-01-24 | Drug product | 2017-02-02 | |
| N204824-001 | 9629959 | 2026-01-24 | Drug product | 2017-05-25 | |
| N204824-001 | 8021335 | 2026-10-04 | Drug product | 2013-11-04 | |
| N204824-001 | 10709844 | 2029-03-10 | Drug product | 2020-08-14 | |
| N204824-001 | 11684723 | 2029-03-10 | Drug product | 2023-07-19 | |
| N204824-001 | 9867949 | 2029-03-10 | Drug product | 2020-08-14 | |
| N204824-001 | 11497753 | 2030-03-19 | Drug product | 2022-12-13 | |
| N204824-001 | 12357642 | 2030-03-19 | Drug product | 2025-08-15 | |
| N204824-001 | 8480631 | 2030-03-19 | U-1442 | Drug product | 2013-11-04 |
| N204824-001 | 8579865 | 2030-03-19 | U-1442 | Drug product | 2013-11-21 |
| N204824-001 | 8945063 | 2030-03-19 | U-1442 | Drug product | 2015-03-02 |
| N204824-001 | 9421333 | 2030-03-19 | U-1442 | Drug product | 2016-09-21 |
| N204824-001 | 8814834 | 2031-05-27 | Drug product | 2020-08-14 | |
| N204824-002 | 11446441 | 2026-01-24 | Drug product | 2022-10-19 | |
| N204824-002 | 8562564 | 2026-01-24 | Drug product | 2013-11-04 | |
| N204824-002 | 9533102 | 2026-01-24 | Drug product | 2017-02-02 | |
| N204824-002 | 9629959 | 2026-01-24 | Drug product | 2017-05-25 | |
| N204824-002 | 8021335 | 2026-10-04 | Drug product | 2013-11-04 | |
| N204824-002 | 10709844 | 2029-03-10 | Drug product | 2020-08-14 | |
| N204824-002 | 11684723 | 2029-03-10 | Drug product | 2023-07-19 | |
| N204824-002 | 9867949 | 2029-03-10 | Drug product | 2020-08-14 | |
| N204824-002 | 11497753 | 2030-03-19 | Drug product | 2022-12-13 | |
| N204824-002 | 12357642 | 2030-03-19 | Drug product | 2025-08-15 | |
| N204824-002 | 8480631 | 2030-03-19 | U-1442 | Drug product | |
| N204824-002 | 8579865 | 2030-03-19 | U-1442 | Drug product | 2013-11-21 |
| N204824-002 | 8945063 | 2030-03-19 | U-1442 | Drug product | 2015-03-02 |
| N204824-002 | 9421333 | 2030-03-19 | U-1442 | Drug product | 2016-09-21 |
| N204824-002 | 8814834 | 2031-05-27 | Drug product | 2020-08-14 | |
| N204824-003 | 11446441 | 2026-01-24 | Drug product | 2022-10-19 | |
| N204824-003 | 8562564 | 2026-01-24 | Drug product | 2013-11-04 | |
| N204824-003 | 9533102 | 2026-01-24 | Drug product | 2017-02-02 | |
| N204824-003 | 9629959 | 2026-01-24 | Drug product | 2017-05-25 | |
| N204824-003 | 8021335 | 2026-10-04 | Drug product | 2013-11-04 | |
| N204824-003 | 10709844 | 2029-03-10 | Drug product | 2020-08-14 | |
| N204824-003 | 11684723 | 2029-03-10 | Drug product | 2023-07-19 | |
| N204824-003 | 9867949 | 2029-03-10 | Drug product | 2020-08-14 | |
| N204824-003 | 11497753 | 2030-03-19 | Drug product | 2022-12-13 | |
| N204824-003 | 12357642 | 2030-03-19 | Drug product | 2025-08-15 | |
| N204824-003 | 8480631 | 2030-03-19 | U-1442 | Drug product | |
| N204824-003 | 8579865 | 2030-03-19 | U-1442 | Drug product | 2013-11-21 |
| N204824-003 | 8945063 | 2030-03-19 | U-1442 | Drug product | 2015-03-02 |
| N204824-003 | 9421333 | 2030-03-19 | U-1442 | Drug product | 2016-09-21 |
| N204824-003 | 8814834 | 2031-05-27 | Drug product | 2020-08-14 | |
| N204824-004 | 11446441 | 2026-01-24 | Drug product | 2022-10-19 | |
| N204824-004 | 8562564 | 2026-01-24 | Drug product | 2013-11-04 | |
| N204824-004 | 9533102 | 2026-01-24 | Drug product | 2017-02-02 | |
| N204824-004 | 9629959 | 2026-01-24 | Drug product | 2017-05-25 | |
| N204824-004 | 8021335 | 2026-10-04 | Drug product | 2013-11-04 | |
| N204824-004 | 10709844 | 2029-03-10 | Drug product | 2020-08-14 | |
| N204824-004 | 11684723 | 2029-03-10 | Drug product | 2023-07-19 | |
| N204824-004 | 9867949 | 2029-03-10 | Drug product | 2020-08-14 | |
| N204824-004 | 11497753 | 2030-03-19 | Drug product | 2022-12-13 | |
| N204824-004 | 12357642 | 2030-03-19 | Drug product | 2025-08-15 | |
| N204824-004 | 8480631 | 2030-03-19 | U-1442 | Drug product | |
| N204824-004 | 8579865 | 2030-03-19 | U-1442 | Drug product | 2013-11-21 |
| N204824-004 | 8945063 | 2030-03-19 | U-1442 | Drug product | 2015-03-02 |
| N204824-004 | 9421333 | 2030-03-19 | U-1442 | Drug product | 2016-09-21 |
| N204824-004 | 8814834 | 2031-05-27 | Drug product | 2020-08-14 | |
| N204824-005 | 11446441 | 2026-01-24 | Drug product | 2022-10-19 | |
| N204824-005 | 8562564 | 2026-01-24 | Drug product | 2014-12-02 | |
| N204824-005 | 9533102 | 2026-01-24 | Drug product | 2017-02-02 | |
| N204824-005 | 9629959 | 2026-01-24 | Drug product | 2017-05-25 | |
| N204824-005 | 8021335 | 2026-10-04 | Drug product | 2014-12-02 | |
| N204824-005 | 10709844 | 2029-03-10 | Drug product | 2020-08-14 | |
| N204824-005 | 11684723 | 2029-03-10 | Drug product | 2023-07-19 | |
| N204824-005 | 9867949 | 2029-03-10 | Drug product | 2020-08-14 | |
| N204824-005 | 11497753 | 2030-03-19 | Drug product | 2022-12-13 | |
| N204824-005 | 12357642 | 2030-03-19 | Drug product | 2025-08-15 | |
| N204824-005 | 8480631 | 2030-03-19 | U-1442 | Drug product | 2014-12-02 |
| N204824-005 | 8579865 | 2030-03-19 | U-1442 | Drug product | 2014-12-02 |
| N204824-005 | 8945063 | 2030-03-19 | U-1442 | Drug product | 2015-03-02 |
| N204824-005 | 9421333 | 2030-03-19 | U-1442 | Drug product | 2016-09-21 |
| N204824-005 | 8814834 | 2031-05-27 | Drug product | 2020-08-14 | |
| N204824-006 | 11446441 | 2026-01-24 | Drug product | 2022-10-19 | |
| N204824-006 | 8562564 | 2026-01-24 | Drug product | 2016-06-01 | |
| N204824-006 | 9533102 | 2026-01-24 | Drug product | 2017-02-02 | |
| N204824-006 | 9629959 | 2026-01-24 | Drug product | 2017-05-25 | |
| N204824-006 | 8021335 | 2026-10-04 | Drug product | 2016-06-01 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | OTREXUP | 10MG/0.4ML (10MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | OTREXUP | 15MG/0.4ML (15MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-003 | OTREXUP | 20MG/0.4ML (20MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-004 | OTREXUP | 25MG/0.4ML (25MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-005 | OTREXUP | 7.5MG/0.4ML (7.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2014-11-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-006 | OTREXUP | 12.5MG/0.4ML (12.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2016-03-24 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-007 | OTREXUP | 17.5MG/0.4ML (17.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2016-03-24 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-008 | OTREXUP | 22.5MG/0.4ML (22.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2016-03-24 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-009 | OTREXUP PFS | 10MG/0.4ML (10MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-010 | OTREXUP PFS | 15MG/0.6ML (15MG/0.6ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-011 | OTREXUP PFS | 17.5MG/0.7ML (17.5MG/0.7ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-012 | OTREXUP PFS | 20MG/0.8ML (20MG/0.8ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-013 | OTREXUP PFS | 22.5MG/0.9ML (22.5MG/0.9ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-014 | OTREXUP PFS | 25MG/ML (25MG/ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-001 | OTREXUP | 10MG/0.4ML (10MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-002 | OTREXUP | 15MG/0.4ML (15MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-003 | OTREXUP | 20MG/0.4ML (20MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-004 | OTREXUP | 25MG/0.4ML (25MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-005 | OTREXUP | 7.5MG/0.4ML (7.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2014-11-07 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-006 | OTREXUP | 12.5MG/0.4ML (12.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2016-03-24 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-007 | OTREXUP | 17.5MG/0.4ML (17.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2016-03-24 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-008 | OTREXUP | 22.5MG/0.4ML (22.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2016-03-24 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-009 | OTREXUP PFS | 10MG/0.4ML (10MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-010 | OTREXUP PFS | 15MG/0.6ML (15MG/0.6ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-011 | OTREXUP PFS | 17.5MG/0.7ML (17.5MG/0.7ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-012 | OTREXUP PFS | 20MG/0.8ML (20MG/0.8ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-013 | OTREXUP PFS | 22.5MG/0.9ML (22.5MG/0.9ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N204824-014 | OTREXUP PFS | 25MG/ML (25MG/ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N204824-001 | OTREXUP | 10MG/0.4ML (10MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N204824-002 | OTREXUP | 15MG/0.4ML (15MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N204824-003 | OTREXUP | 20MG/0.4ML (20MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N204824-004 | OTREXUP | 25MG/0.4ML (25MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2013-10-11 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N204824-005 | OTREXUP | 7.5MG/0.4ML (7.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2014-11-07 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N204824-006 | OTREXUP | 12.5MG/0.4ML (12.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2016-03-24 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N204824-007 | OTREXUP | 17.5MG/0.4ML (17.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2016-03-24 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N204824-008 | OTREXUP | 22.5MG/0.4ML (22.5MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2016-03-24 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N204824-009 | OTREXUP PFS | 10MG/0.4ML (10MG/0.4ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N204824-010 | OTREXUP PFS | 15MG/0.6ML (15MG/0.6ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N204824-011 | OTREXUP PFS | 17.5MG/0.7ML (17.5MG/0.7ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N204824-012 | OTREXUP PFS | 20MG/0.8ML (20MG/0.8ML) | SOLUTION / SUBCUTANEOUS | RLD | 2017-05-31 | 31067a03dcf5… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 11446441 | 2026-01-24 | Drug product | 2022-10-19 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 8562564 | 2026-01-24 | Drug product | 2013-11-04 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 9533102 | 2026-01-24 | Drug product | 2017-02-02 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 9629959 | 2026-01-24 | Drug product | 2017-05-25 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 8021335 | 2026-10-04 | Drug product | 2013-11-04 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 10709844 | 2029-03-10 | Drug product | 2020-08-14 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 11684723 | 2029-03-10 | Drug product | 2023-07-19 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 9867949 | 2029-03-10 | Drug product | 2020-08-14 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 11497753 | 2030-03-19 | Drug product | 2022-12-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 12357642 | 2030-03-19 | Drug product | 2025-08-15 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 8480631 | 2030-03-19 | U-1442 | Drug product | 2013-11-04 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 8579865 | 2030-03-19 | U-1442 | Drug product | 2013-11-21 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 8945063 | 2030-03-19 | U-1442 | Drug product | 2015-03-02 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 9421333 | 2030-03-19 | U-1442 | Drug product | 2016-09-21 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N204824-001 | 8814834 | 2031-05-27 | Drug product | 2020-08-14 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 11446441 | 2026-01-24 | Drug product | 2022-10-19 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 8562564 | 2026-01-24 | Drug product | 2013-11-04 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 9533102 | 2026-01-24 | Drug product | 2017-02-02 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 9629959 | 2026-01-24 | Drug product | 2017-05-25 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 8021335 | 2026-10-04 | Drug product | 2013-11-04 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 10709844 | 2029-03-10 | Drug product | 2020-08-14 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 11684723 | 2029-03-10 | Drug product | 2023-07-19 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 9867949 | 2029-03-10 | Drug product | 2020-08-14 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 11497753 | 2030-03-19 | Drug product | 2022-12-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 12357642 | 2030-03-19 | Drug product | 2025-08-15 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 8480631 | 2030-03-19 | U-1442 | Drug product | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 8579865 | 2030-03-19 | U-1442 | Drug product | 2013-11-21 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 8945063 | 2030-03-19 | U-1442 | Drug product | 2015-03-02 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 9421333 | 2030-03-19 | U-1442 | Drug product | 2016-09-21 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N204824-002 | 8814834 | 2031-05-27 | Drug product | 2020-08-14 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-003 | 11446441 | 2026-01-24 | Drug product | 2022-10-19 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-003 | 8562564 | 2026-01-24 | Drug product | 2013-11-04 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-003 | 9533102 | 2026-01-24 | Drug product | 2017-02-02 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-003 | 9629959 | 2026-01-24 | Drug product | 2017-05-25 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-003 | 8021335 | 2026-10-04 | Drug product | 2013-11-04 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-003 | 10709844 | 2029-03-10 | Drug product | 2020-08-14 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-003 | 11684723 | 2029-03-10 | Drug product | 2023-07-19 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-003 | 9867949 | 2029-03-10 | Drug product | 2020-08-14 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-003 | 11497753 | 2030-03-19 | Drug product | 2022-12-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N204824-003 | 12357642 | 2030-03-19 | Drug product | 2025-08-15 | caaa826d4ba7… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Otrexup | METHOTREXATE | Antares Pharma, Inc. | 9ab8ce16-f7de-41d4-a4c8-1c742621b6d5 | 2025-01-31 | Boxed warning, Warnings, Adverse reactions | 204824 NDA204824 54436-015 54436-022 54436-025 54436-012 54436-017 54436-010 54436-020 |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 54436-010 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-010 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-010 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-010 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-010 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-010 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-012 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-012 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-012 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-012 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-012 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-012 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-015 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-015 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-015 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-015 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-015 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-015 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-017 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-017 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-017 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-017 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-017 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-017 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-020 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-020 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-020 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-020 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-020 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-020 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-022 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-022 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-022 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-022 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-022 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-022 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-025 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-025 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-025 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-025 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-025 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
| 54436-025 | Otrexup | methotrexate | Antares Pharma, Inc. | NDA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 61504 | SUPPL | 2020-01-02 |
| 61463 | SUPPL | 2019-12-27 |
| 59290 | ORIG | 2019-07-09 |
| 59289 | ORIG | 2019-07-09 |
| 59288 | ORIG | 2019-07-09 |
| 59136 | SUPPL | 2019-06-20 |
| 59129 | SUPPL | 2019-06-20 |
| 53062 | SUPPL | 2018-03-20 |
| 53044 | SUPPL | 2018-03-16 |
| 49087 | SUPPL | 2017-07-27 |
| 19606 | SUPPL | 2016-05-27 |
| 10402 | SUPPL | 2014-11-12 |
| 40426 | SUPPL | 2014-11-10 |
| 43480 | ORIG | 2014-02-03 |
| 19605 | ORIG | 2013-10-17 |
| 32597 | ORIG | 2013-10-16 |